RT Journal Article
T1 Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.
A1 Provencio, Mariano
A1 Sabín, Pilar
A1 Gomez-Codina, Jose
A1 Torrente, Maria
A1 Calvo, Virginia
A1 Llanos, Marta
A1 Gumá, Josep
A1 Quero, Cristina
A1 Blasco, Ana
A1 Cruz, Miguel Angel
A1 Aguiar, David
A1 García-Arroyo, Francisco
A1 Lavernia, Javier
A1 Martinez, Natividad
A1 Morales, Manuel
A1 Saez-Cusi, Alvaro
A1 Rodriguez, Delvys
A1 de la Cruz, Luis
A1 Sanchez, Jose Javier
A1 Rueda, Antonio
A1 GOTEL (Spanish Lymphoma Oncology Group), 
AB Follicular lymphoma is the second most common non-Hodgkin lymphoma in the United States and Europe. However, most of the prospective randomized studies have very little follow-up compared to the long natural history of the disease. The primary aim of this study was to investigate the long-term survival of our series of patients with follicular lymphoma. A total of 1074 patients with newly diagnosed FL were enrolled. Patients diagnosed were prospectively enrolled from 1980 to 2013. Median follow-up was 54.9 months and median overall survival is over 20 years in our series. We analyzed the patients who are still alive beyond 10 years from diagnosis in order to fully assess the prognostic factors that condition this group. Out of 166 patients who are still alive after more than 10 years of follow-up, 118 of them (73%) are free of evident clinical disease. Variables significantly associated with survival at 10 years were stage  A longer follow-up and a large series demonstrated a substantial population of patients with follicular lymphoma free of disease for more than 10 years.
YR 2017
FD 2017-05-11
LK https://hdl.handle.net/10668/27043
UL https://hdl.handle.net/10668/27043
LA en
DS RISalud
RD Feb 23, 2025